Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

[1]  A. Manning,et al.  Aurora A inhibition limits centrosome clustering and promotes mitotic catastrophe in cells with supernumerary centrosomes , 2018, bioRxiv.

[2]  Robert K. Stuart,et al.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[4]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[5]  Traci M. Blonquist,et al.  Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia , 2016, Haematologica.

[6]  J. Aster,et al.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. , 2016, The Journal of molecular diagnostics : JMD.

[7]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[8]  D. Neuberg,et al.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.

[9]  A. Rao,et al.  Acute myeloid leukemia and myelodysplastic syndromes in older adults. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Westervelt,et al.  An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes , 2014, Leukemia research reports.

[11]  J. Crispino,et al.  The Aurora Kinases in Cell Cycle and Leukemia , 2014, Oncogene.

[12]  C. Bloomfield,et al.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Giles,et al.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism , 2012, International journal of cancer.

[14]  K. Venkatakrishnan,et al.  Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations , 2012, Clinical Cancer Research.

[15]  J. Baselga,et al.  Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[16]  F. Giles,et al.  Targeting aurora kinases in cancer treatment. , 2011, Current drug targets.

[17]  E. Estey,et al.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Rego,et al.  High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. , 2011, Leukemia research.

[19]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[20]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[21]  H. Kantarjian,et al.  Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia , 2008, Journal of hematopathology.

[22]  Qing Jiang,et al.  Roles of Aurora Kinases in Mitosis and Tumorigenesis , 2007, Molecular Cancer Research.

[23]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[24]  Eiji Kohmura,et al.  Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells* , 2003, Journal of Biological Chemistry.

[25]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[27]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[28]  Brown Bw,et al.  Confidence limits for probability of response in multistage phase II clinical trials. , 1985 .

[29]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[30]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.